Generics 16

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Carbidopa manufacturers

16 products found

Filters

Filters

Filters , active

Country of origin : India

Clear all

16 products found

carbidopa + levodopa

Tablets for oral solution 50 mg + 200 mg, 25 mg + 100 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19884

Manufacturer usually replies in 6 days

levodopa + carbidopa + entacapone

Tablets 50 mg + 12.5 mg + 200 mg , 75 mg + 18.75 mg + 200 mg , 100 mg + 25 mg + 200 mg, 125 mg + 31.25 mg + 200 mg, 150 mg + 37.5 mg + 200 mg , 200 mg + 50 mg + 200 mg , 175 mg + 43.75 mg + 200 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Manufacturer #15189
The company, which was founded in 1989, is involved in developing, manufacturing, and distributing a wide range of formulations for anti-infectives, cardiovascular, anti-diabetic, dermatological, and hormone treatment. The corporation has a global presence in 170 + countries, 60+ WHO-prequalified medications, and 3700+ product registrations.

Manufacturer usually replies in 9 days

levodopa + carbidopa

Tablets 100 mg + 25 mg, 200 mg + 50 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Manufacturer #18140

Manufacturer usually replies in 7 days

levodopa + carbidopa

Tablets 250 mg + 25 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #20848

Manufacturer usually replies in 3 days

levodopa + carbidopa

Tablets 100 mg + 10 mg, 250 mg + 25 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #20336

Manufacturer usually replies in 4 days

levodopa + carbidopa

Tablets 250 mg+25 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19223

Manufacturer usually replies in 4 days

levodopa + carbidopa

Tablets, orally disintegrating (ODT) 100 mg + 10 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #18530

Manufacturer usually replies in 4 days

levodopa + carbidopa + entacapone

Tablets 50mg+12,5mg+200mg, 75mg+18,75mg+200mg, 100mg+25mg+200mg, 125mg+31,25mg+200mg, 150mg+37,5mg+200mg, 200mg+50mg+200mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
Manufacturer #4205

Manufacturer usually replies in 4 days

levodopa + carbidopa

Tablets 100 mg + 10 mg, 100 mg + 25 mg, 200 mg + 50 mg, 250 mg + 25 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP, WHO
Manufacturer #2303

Manufacturer usually replies in 6 days

levodopa + carbidopa

Tablets 275 mg, 10 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
GMP, WHO
Manufacturer #24869

Manufacturer usually replies in 3 days

levodopa + carbidopa

Tablets 100 mg + 10 mg, 250 mg + 25 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #20401

Manufacturer usually replies in 5 days

levodopa + carbidopa

Tablets 275 mg + 110 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #20087

Manufacturer usually replies in 8 days

methyldopa + carbidopa

Tablets 250 mg+25 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19639

Manufacturer usually replies in 12 days

levodopa + carbidopa

Tablets 100 mg + 10 mg, 100 mg + 25 mg, 250 mg + 25 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #31070

Manufacturer usually replies in nan days

levodopa + carbidopa

Tablets 100 mg + 25 mg, 250 mg + 25 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
PICS
Manufacturer #31069

Manufacturer usually replies in nan days

entacapone + levodopa + carbidopa

Tablets 200 mg + 100 mg + 25 mg, 200 mg + 150 mg + 37.5 mg, 200 mg + 50 mg + 12.5 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP, WHO
Manufacturer #2303

Manufacturer usually replies in 6 days

Carbidopa

Carbidopa is a drug used in the treatment of Parkinson's disease in order to inhibit peripheral metabolism of levodopa. This property is significant because allows a greater proportion of peripheral levodopa to cross the blood–brain barrier for central nervous system effect, thus paving way for the best possible absorption. Parkinson’s disease damages the neurons that produce dopamine, the motor symptoms of PD appear, including tremor, rigidity, impaired balance, and includes loss of spontaneous movement. These are motor symptoms of PD related to depletion of the neurotransmitter (chemical messenger) dopamine in the brain. Carbidopa prevents the conversion of L-DOPA to dopamine peripherally, thus reducing the side effects caused by dopamine on the periphery, and finally increasing the concentration of L-DOPA and dopamine in the brain.
Many combinations of Carbidopa/levodopa carry the brand names of Kinson, Sinemet, Pharmacopa and Atamet.
Amerigens Pharmaceuticals Ltd, first approved product by the FDA containing only carbidopa in 2014. Initially, The combination treatment of carbidopa/levodopa was originally developed by Watson Labs, However, the historical information by the FDA brings back to the approval of this combination therapy by Mayne Pharma in 1992.

Forms and dosage

The combination of levodopa/carbidopa is sold as a regular tablet, an orally disintegrating tablet, an extended-release, long-acting tablet, and an extended-release, long-acting capsule to take by mouth. It is also sold as a suspension to be given into your stomach through a PEG-J tube or sometimes through a naso-jejunal tube using a special infusion pump.
The regular and orally disintegrating tablets are given three or four times a day and extended-
release capsule is usually taken three to five times a day. The suspension is usually given as a morning dose by infusion over 10 to 30 minutes and then as a continuous dose given by infusion over 16 hours.

The cost of Carbidopa

In the USA, the consumers have to pay an average retail price of $44.23 and in the UK a supply of 100 tablets of 25mg strength cost 35 pounds. In India, the same supply costs less than dollar for a generic brand.

How does it work?

Carbidopa works by inhibiting aromatic-L-amino-acid decarboxylase, an enzyme important in the biosynthesis of L-tryptophan to serotonin and in the biosynthesis of L-DOPA to dopamine (DA). Increased dopamine availability increases the effectiveness of the remaining neurons thus providing alleviation from symptoms for a time. However, exogenously provided, L-DOPA gets metabolized peripherally before reaching the blood–brain barrier. But, Carbidopa decreases peripheral DDC conversion of L-DOPA before it crosses the blood–brain barrier. Carbidopa acts as a peripheral DDC inhibitor, it has no effect on brain DDC conversion of L-DOPA to dopamine. As result of these actions, a greater proportion of the exogenously provided levodopa/L-DOPA reaches the brain

Finding Carbidopa Manufacturers and Suppliers

 
For sourcing Carbidopa, manufacturers and sellers, log onto Pipelinepharma’s B2B online market place. It is a sophisticated B2B marketplace platform which is powered by our intuitive interface, which helps you narrow down and compare options for you to make the best decision.
 
Pipelinepharma’s B2B online market place has a host of manufacturers and suppliers, making it the ideal sourcing platform. You can choose from the wide list of manufacturers and suppliers suitable for your specific sourcing and pricing needs.